Synairgen plc

A Tall Order For The Pace Of M&A December was a red-letter month for biotechnology companies as the large number of acquisitions that were ether completed or announced propelled the NASDAQ Biotech Ind

The chances of Synairgen bringing its inhaled COVID-19 candidate to market have dwindled after a failure in a hospital-based Phase III trial. The Southampton, UK-based company has been developing it

The therapeutic solutions and vaccines developed by the biopharma industry during the pandemic have allowed society to start imagining life after COVID-19. However, more tools and treatments are neede

Valneva SE ’s candidate COVID-19 vaccine, VLA2001, is expected to begin a rolling review at the European Medicines Agency “shortly,” says the French company, which has also announced that the European